Gracell Biotechnologies Management
Management criteria checks 2/4
Gracell Biotechnologies' CEO is William Cao, appointed in May 2017, has a tenure of 6.75 years. directly owns 15.56% of the company’s shares, worth $154.19M. The average tenure of the management team and the board of directors is 2.6 years and 3.9 years respectively.
Key information
William Cao
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.8yrs |
| CEO ownership | 15.6% |
| Management average tenure | 2.6yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)
Feb 21Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform
Sep 22Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02
Aug 15Gracell Biotechnologies rallies after naming new chief medical officer
Aug 01Gracell names Dr. Samuel Zhang as Chief Business Officer
Jul 19Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Nov 26Gracell ends IPO quiet period with favorable views from analysts
Feb 02CEO
William Cao (64 yo)
6.8yrs
Tenure
Dr. Wei Cao, also known as William, Ph D., B.M, serves as Founder Gracell Biotechnologies Inc and has been its Chairman and Chief Executive Officer of Gracell Biotechnologies Inc since May 2017. Dr. Cao is...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.8yrs | no data | 15.56% $ 154.2m | |
| Chief Financial Officer | 3.6yrs | no data | no data | |
| Chief Business Officer | 1.6yrs | no data | no data | |
| Chief Medical Officer | 1.5yrs | no data | no data | |
| Executive Officer | no data | no data | no data |
2.6yrs
Average Tenure
59.5yo
Average Age
Experienced Management: GRCL's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.8yrs | no data | 15.56% $ 154.2m | |
| Independent Director | 2.6yrs | no data | no data | |
| Director | 3.9yrs | no data | no data | |
| Independent Director | 5yrs | no data | no data | |
| Independent Director | 3.1yrs | no data | no data |
3.9yrs
Average Tenure
62yo
Average Age
Experienced Board: GRCL's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/21 06:34 |
| End of Day Share Price | 2024/02/21 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gracell Biotechnologies Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Louise Chen | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |